Koshinski Asset Management Inc. Sells 1,420 Shares of Johnson & Johnson (NYSE:JNJ)

Koshinski Asset Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, HoldingsChannel reports. The firm owned 45,057 shares of the company’s stock after selling 1,420 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Johnson & Johnson were worth $6,516,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Priebe Wealth Holdings LLC increased its position in shares of Johnson & Johnson by 39.3% during the fourth quarter. Priebe Wealth Holdings LLC now owns 1,817 shares of the company’s stock worth $263,000 after acquiring an additional 513 shares in the last quarter. Hoese & Co LLP increased its position in shares of Johnson & Johnson by 15.6% during the fourth quarter. Hoese & Co LLP now owns 2,502 shares of the company’s stock worth $362,000 after acquiring an additional 338 shares in the last quarter. Wealthquest Corp increased its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. Wealthquest Corp now owns 9,277 shares of the company’s stock worth $1,342,000 after acquiring an additional 115 shares in the last quarter. Amplius Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 16.1% during the fourth quarter. Amplius Wealth Advisors LLC now owns 5,234 shares of the company’s stock worth $757,000 after acquiring an additional 727 shares in the last quarter. Finally, Gemmer Asset Management LLC increased its position in shares of Johnson & Johnson by 11.0% during the fourth quarter. Gemmer Asset Management LLC now owns 9,298 shares of the company’s stock worth $1,345,000 after acquiring an additional 923 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 1.9 %

JNJ opened at $145.39 on Thursday. The stock has a market cap of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $148.26 and its two-hundred day moving average price is $156.12. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. As a group, equities analysts expect that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 71.78%.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $173.27.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.